Evidence map›Paper›PMID 24623550›Full record

ArticleStatistics in medicine2014

Analyzing longitudinal data to characterize the accuracy of markers used to select treatment.

Colleen M Sitlani, Patrick J Heagerty

Abstract read
In one paragraph

Article in Statistics in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Sensitivity, Specificity, PPV, and NPV for Predictive Biomarkers.Journal of the National Cancer Institute · 2015
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Colleen M SitlaniDepartment of Medicine, University of Washington, Seattle, WA, U.S.A.
Patrick J Heagerty
University of Washington · US

Funding

Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Use of Biomarkers in Diagnosis, Prognosis, Risk Prediction and Early Detection ofP01CA053996 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HSU, LI · 1991 to 2015
$9.4M
Statistical Methods for Longitudinal StudiesR01HL072966 · NHLBI · UNIVERSITY OF WASHINGTON · PI HEAGERTY, PATRICK J · 2003 to 2014
$1.9M
CARDIOVASCULAR BIOSTATISTICS TRAININGT32HL007183 · NHLBI · UNIVERSITY OF WASHINGTON · PI RICE, KENNETH M. · 1985 to 2011
$1.8M
NCATS NIH HHS UL1 TR000423NCI NIH HHS P01 CA053996NHLBI NIH HHS R01 HL072966NHLBI NIH HHS T32 HL007183NHLBI NIH HHS T32 HL07183
6 · The paper itself

Abstract

With the increasing availability of detailed clinical information, there is optimism that treatment choices can be selectively directed to those individuals most likely to benefit. While standard clinical trials can establish whether a treatment appears to be effective on average, subsequent work is needed to determine whether there are identifiable subgroups of subjects for whom treatment is either particularly beneficial or harmful. Molecular assays and modern imaging technology now allow numerous candidate measures to be used as potential determinants of treatment choice. In this manuscript, we focus on novel measures of decision accuracy that reflect the treatment marker objective. Specifically, we define longitudinal individual-level potential outcomes (principal strata) that characterize patient outcomes under treated and untreated states. We propose generalizations of sensitivity and specificity that measure the accuracy with which a marker can distinguish those subjects who are expected to have a more favorable outcome under a specific treatment choice from those subjects who are expected to have a more favorable outcome under alternative treatment options. For quantitative markers, we propose principal receiver operating characteristic curves that display the full range of potential sensitivity and specificity. We use simulations to demonstrate the properties of proposed estimators, and we illustrate the methods using candidate neuroimaging and electrodiagnostic markers that could be used to select patients for carpal tunnel surgery.

Indexed as

Data Interpretation, StatisticalLongitudinal StudiesPredictive Value of TestsBiomarkersCarpal Tunnel SyndromeComputer SimulationElectrodiagnosisHumansMagnetic Resonance ImagingModels, StatisticalROC CurveBiomarkerscausal inferenceclassification and predictionlongitudinal data analysistreatment selection

Identifiers

PMID24623550
PMCPMC4097886
OpenAlexW1932186799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.